# US 2024/0199793 A1 · Thermoplastic biodegradable elastomers and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199793 A1
- Document ID: US20240199793A1
- Status: Published application
- Kind: A1
- Application number: 18/017,948
- Filed: 2021-08-05
- Published: 2024-06-20
- Earliest claimed: 2020-08-06
- Assignees: Regents of the University of Minnesota
- Applicants: Regents of the University of Minnesota
- Inventors: Wei Shen; Ronald A. Siegel; Sudipta Panja
- Web page: https://patentgrep.com/patent/US20240199793A1

## CPC

- C08G 63/08: Lactones or lactides
- A61K 38/47: acting on glycosyl compounds (3.2), e.g. cellulases, lactases
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/54: Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)}
- A61L 27/58: Materials at least partially resorbable by the body
- C08L 87/005: {Block or graft polymers not provided for in groups C08L1/00 - C08L85/04}
- C12Y 302/01017: Lysozyme (3.2.1.17)
- A61L 2300/414: Growth factors
- C08L 2201/06: Biodegradable
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08L: COMPOSITIONS OF MACROMOLECULAR COMPOUNDS (compositions based on polymerisable monomers C08F, C08G; artificial filaments or fibres D01F; textile treating compositions D06)
- C12Y: ENZYMES

## Abstract

Methods including providing a block copolymer, the block copolymer comprising at least a polycaprolactone (PCL) block; and a second block being amorphous and having a glass transition temperature less than 30° C.; and subjecting the block copolymer to thermal processing at a temperature less than 100° C. Articles and thermoprocessing methods utilizing such block copolymers are also disclosed herein.

## Claims

### Claim 1

A method of using a block copolymer, the method comprising:
providing a block copolymer, the block copolymer comprising at least a polycaprolactone (PCL) block; and
a second block being amorphous and having a glass transition temperature less than 30° C.; and
subjecting the block copolymer to thermal processing at a temperature less than 100° C.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the second block comprises a poly(P-methyl-6-valerolactone) (PMVL) block.

### Claim 3 (depends on 1)

A method according to claim 1, wherein the second block comprises amorphous poly(caprolactone-co-lactide), poly(lactide-co-trimethylene carbonate), polyurethane, poly(trimethylene carbonate), poly(ester ether), polyhydroxyalkanoates, or combinations thereof.

### Claim 4 (depends on 2)

A method according to claim 2, wherein the PMVL block has a mass average molar mass (Mw) of 10 kDa or greater.

### Claim 5 (depends on 1, 2, 3, 4)

A method according to any of claims 1 to 4, wherein the thermal processing occurs at a temperature less than 70° C.

### Claim 6 (depends on 1, 2, 3, 4)

A method according to any of claims 1 to 4, wherein the thermal processing occurs at a temperature less than 65° C.

### Claim 7 (depends on 1, 2, 3, 4)

A method according to any of claims 1 to 4, wherein the thermal processing occurs at a temperature from 50° C. to 60° C.

### Claim 8 (depends on 1, 2, 3, 4)

A method according to any of the claims 1 to 4 further comprising combining a bioactive agent with the block copolymer before, while being subjected to thermal processing, or both.

### Claim 9 (depends on 8)

A method according to claim 8, wherein the thermal processing is three dimensional (3D) printing, extrusion, molding, or some combination thereof.

### Claim 10 (depends on 8)

A method according to claim 8, wherein the bioactive agent is a protein.

### Claim 11 (depends on 8)

A method according to claim 8, wherein each block has an Mw of about 10 kDa or greater.

### Claim 12 (depends on 8)

A method according to claim 8, wherein the PMVL block has a 14C/12C ratio greater than zero.

### Claim 13 (depends on 8)

A method according to claim 8, wherein the block copolymer has a 14C/12C ratio greater than zero.

### Claim 14 (depends on 8)

A method according to claim 8, wherein the block copolymer is an ABA block copolymer, wherein the mid-block comprises a second block being amorphous and has a glass transition temperature less than 30° C., and wherein the end blocks are the PCL blocks.

### Claim 15 (depends on 14)

The method according to claim 14, wherein the mid-block comprises amorphous poly(caprolactone-co-lactide), polyurethane, poly(trimethylene carbonate), Poly(ester ether), and random copolymers formed from caprolactone and any other monomers that can disrupt the crystalline structure of the resulting polymers

### Claim 16

An article comprising:
a block copolymer, the block copolymer comprising at least a polycaprolactone (PCL) block, and a second block having a glass transition temperature less than 30° C.; and
at least one bioactive agent,
wherein the article was formed using a thermal processing method at a temperature of less than 100° C.

### Claim 17 (depends on 16)

The article according to claim 16, wherein the at least one bioactive agent is selected from: growth factors, cytokines, small molecules and combinations thereof.

### Claim 18 (depends on 16, 17)

The article according to any of claims 16 to 17, wherein the growth factors, cytokines, or combinations thereof are selected from: vascular endothelial growth factor (VEGF), Platelet-derived growth factor (PDGF), basic fibroblast growth factor (bFGF), acidic fibroblast growth factor (aFGF), hepatocyte growth factor (HGF), insulin-like growth factor-1 (IGF-1), stromal-cell derived factor 1 (SDF-1), nerve growth factor (NGF), neurotrophin 3 (NT-3), brain-derived neurotrophic factor (BDNF), glial-derived neurotrophic factor (GDNF), glial growth factor (GGF), ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), growth differentiation factor 5 (GDF-5), Erythropoietin (EPO), interleukin-4 (IL-4), interleukin-2 (IL-2), interferon gamma (IFN-γ), and combinations thereof.

### Claim 19 (depends on 16, 17)

The article according to claim 16 to 17, wherein the bioactive agent is a small molecule.

### Claim 20 (depends on 17)

The article according to claim 17, wherein the small molecule is selected from the group consisting of: paclitaxel, carmustine, gemcitabine, histrelin, leuprolide, goserelin, corticosteroids, simvastatin, risperidone, tacrolimus, vancomycin, lidocaine, buprenorphine, hydromorphine, levonorgestrel, estradiol, etonogestrel, and combinations thereof.

### Claim 21 (depends on 16, 17)

The article according to any of claims 16 to 17, wherein the article has an elastic modulus from 0.01 MPa to about 2500 MPa.

### Claim 22 (depends on 16, 17)

The article according to any of claims 16 to 17, wherein the article has an elastic modulus from about 1.5 MPa to about 300 MPa.

### Claim 23 (depends on 16, 17)

The article according to any of claims 16 to 17, wherein the article has a percent elongation of from about 5% to about 5000%.

### Claim 24 (depends on 16, 17)

The article according to any of claims 16 to 17, wherein the article has a percent elongation from about 300% to about 2000%.

### Claim 25 (depends on 16, 17)

The article according to any of claims 16 to 17, wherein the article is formed using 3D printing, extrusion, molding, or some combination thereof
